trial summary · NCT07885319
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
A Phase 1b/2, Open-Label, Multicenter, Single-Arm Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Malignant Pleural Mesothelioma, Advanced, sponsored by Ruijin Hospital. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.
Source record: https://clinicaltrials.gov/study/NCT07885319
Facts
| registry id | NCT07885319 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Malignant Pleural Mesothelioma, Advanced |
| sponsor | Ruijin Hospital |
| sponsor class | OTHER |
| enrollment | 78 |
| start date | 2026-11-01 |
| primary completion | 2028-11-30 |
| completion | 2028-11-30 |
| results posted | not reported |
Conditions
- Malignant Pleural Mesothelioma, Advanced
Interventions
- Ivonescimab Combined With Chemotherapy
Countries
- China
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.